SRNE - Sorrento sees positive results in Phase 1B trial of Resiniferatoxin Epidural in cancer patients with reported intractable pain

Seventeen subjects with advanced cancer pain received epidural RTX (0.4 to 25 mcg). No dose limiting toxicities were reported, and a majority of patients reported meaningful pain reduction of 30% or more vs. baseline.Sorrento (SRNE) expects to immediately submit to the FDA a request to proceed with a Phase 3 trial.Shares are on the move higher, now ahead 3.9% for the day.Source: Press Release

For further details see:

Sorrento sees positive results in Phase 1B trial of Resiniferatoxin Epidural in cancer patients with reported intractable pain